annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 9A Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell
carcinoma (RCC). (Abstract #4630)
A. J. Bullock, L. Zhang, A. M. O’Neill, A. Percy, V. Sukhatme, J. W. Mier,
M. B. Atkins, R. S. Bhatt
Brd. 9B Serum lactate dehydrogenase (LDH) as a biomarker for survival with
mTOR inhibition in patients with metastatic renal cell carcinoma (RCC).
(Abstract #4631)
A. J. Armstrong, D. J. George, S. Halabi
Brd. 9C A phase III protocol of androgen suppression (AS) and radiation therapy (RT)
versus AS and RT followed by chemotherapy with paclitaxel, estramustine,
and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902.
(Abstract #4632)
H. M. Sandler, D. Hunt, A. O. Sartor, L. G. Gomella, A. Hartford, K. L. Zeitzer,
R. Rajan, K. Kerlin, J. M. Michalski, S. A. Rosenthal
Brd. 9D Treatment of intermediate- or high-risk prostate cancer by dose escalation
with high-dose 3D-conformal radiotherapy (HD-3D-CRT) or low-dose 3Dconformal
radiotherapy plus HDR brachytherapy (LD-3D-CRT�HDR-B):
Early results of a prospective comparative trial. (Abstract #4633)
B. Guix, J. Bartrina, J. Tello, L. Quinzaños, J. Sole, T. Lacorte, J. Fernandez,
I. Guix, G. Galdon, M. Espino
Brd. 9E Phase I/II trial of combined hormonal therapy and hypofractionated
accelerated radiotherapy with concomitant intensity-modulated boost for
high-risk prostate cancer: Toxicity analysis. (Abstract #4634)
H. Quon, D. A. Loblaw, G. Morton, E. Szumacher, C. Danjoux, R. Choo,
G. Thomas, A. Kiss, A. Deabreu, P. Cheung
Brd. 9F Molecular profiling of circulating tumor cells (CTC) in patients with castrate
metastatic prostate cancer (CMPC) receiving abiraterone acetate (AA) after
failure of docetaxel-based chemotherapy. (Abstract #4635)
D. C. Danila, A. Anand, C. C. Sung, M. Leversha, D. E. Rathkopf, M. J. Morris,
S. F. Slovin, A. Molina, M. Fleisher, H. I. Scher
Brd. 9G A sensitive exosome-based biosignature for the diagnosis of prostate
cancer. (Abstract #4636)
C. Kuslich, T. L. Pawlowski, T. Deng, T. Tinder, J. Kim, J. Kimbrough, D. Spetzler
Brd. 9H Use of changes in serum alkaline phosphatase to predict survival
independent of PSA changes in men with castration-resistant prostate
cancer and bone metastasis receiving chemotherapy: A retrospective
analysis of the TAX327 trial. (Abstract #4637)
G. R. Pond, G. Sonpavde, W. R. Berry, R. De Wit, A. J. Armstrong,
M. A. Eisenberger, I. Tannock
Brd. 10A Fluorodeoxyglucose (FDG) PET as an outcome measure for metastatic
prostate cancer. (Abstract #4638)
M. J. Morris, J. J. Fox, E. R. Dennis, K. Tse, E. Flatts, G. Heller, X. Jia, H. Schöder,
S. M. Larson, H. I. Scher
Brd. 10B Association of genetic polymorphisms in ERCC1 gene with PSA response to
carboplatin chemotherapy in men with metastatic castration-resistant
prostate cancer (CRPC). (Abstract #4639)
M. Nakabayashi, W. K. Oh, L. Werner, W. Xie, M. M. Regan, T. J. McKearn,
P. Kantoff, M. Pomerantz
Brd. 10C Serum-free circulating DNA as a biomarker of prostate cancer diagnosis.
(Abstract #4640)
E. Gordian, K. Ramachandran, I. M. Reis, M. Manoharan, M. S. Soloway, R. Singal
Brd. 10D Correlation between serum PSA and testosterone (T) kinetics in patients
(pts) with biochemically relapsed prostate cancer (BRPC) (M0), after local
treatment (tx), treated with intermittent androgen deprivation (IAD).
(Abstract #4641)
V. J. Sinibaldi, D. Keizman, M. A. Carducci, S. R. Denmeade, P. Huang,
M. A. Eisenberger
364